In a report released yesterday, Chris O`Cull from Stifel Nicolaus maintained a Hold rating on Portillo’s (PTLO – Research Report), with a price target of $25.00. The company’s shares closed yesterday at $24.97.
According to TipRanks, O`Cull is a 5-star analyst with an average return of 13.6% and a 63.91% success rate. O`Cull covers the Services sector, focusing on stocks such as Chipotle, Jack In The Box, and Papa John’s International.
Portillo’s has an analyst consensus of Moderate Buy, with a price target consensus of $26.25, representing a 5.13% upside. In a report released on August 8, Morgan Stanley also maintained a Hold rating on the stock with a $23.00 price target.
Based on Portillo’s’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $134.48 million and a net profit of $194 thousand. In comparison, last year the company earned a revenue of $140.73 million and had a net profit of $13.75 million
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTLO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli’s pasta, sides and soup, and desserts and shakes.
Read More on PTLO:
- Stifel Nicolaus Sticks to Their Hold Rating for Restaurant Brands International (QSR)
- Stifel Nicolaus Sticks to Their Buy Rating for Papa John’s International (PZZA)
- Stifel Nicolaus Sticks to Their Buy Rating for SQZ Biotechnologies (SQZ)
- Stifel Nicolaus Keeps Their Buy Rating on Cue Biopharma (CUE)
- AbCellera Biologics (ABCL) Receives a Buy from Stifel Nicolaus